Article Details

CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line ... - Benzinga

Retrieved on: 2022-06-04 20:21:25

Tags for this article:

Click the tags to see associated articles and topics

CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line ... - Benzinga. View article details on hiswai:

Excerpt

... at four years for previously treated patients in ASCEND trial Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca's CALQUENCE®

Article found on: www.benzinga.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up